Based on the Passage Bio Inc stock forecast from 1 analysts, the average analyst target price for Passage Bio Inc is USD 4.00 over the next 12 months. Passage Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Passage Bio Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Passage Bio Inc’s stock price was USD 0.36. Passage Bio Inc’s stock price has changed by +6.62% over the past week, -9.38% over the past month and -72.95% over the last year.
No recent analyst target price found for Passage Bio Inc
No recent average analyst rating found for Passage Bio Inc
Company Overview Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Read Less
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the tr...Read More
Frequently Asked Questions About Passage Bio Inc (PASG) Stock
Based on ratings from 1 analysts Passage Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PASG's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PASG is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PASG's stock to indicate if its overvalued.
The last closing price of PASG's stock was USD 0.36.
The most recent market capitalization for PASG is USD 0.03B.
Based on targets from 1 analysts, the average taret price for PASG is projected at USD 4.00 over the next 12 months.
This means that PASG's stock price may go up by +1,003.45% over the next 12 months.
We can't find any ETFs which contains Passage Bio Inc's stock.
As per our most recent records Passage Bio Inc has 58 Employees.
Passage Bio Inc's registered address is One Commerce Square, Philadelphia, PA, United States, 19103.
You can get more information about it from Passage Bio Inc's website at https://www.passagebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Passage Bio Inc (PASG) Stock
Based on ratings from 1 analysts Passage Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PASG's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PASG is USD 4.00 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PASG's stock to indicate if its overvalued.
The last closing price of PASG's stock was USD 0.36.
The most recent market capitalization for PASG is USD 0.03B.
Based on targets from 1 analysts, the average taret price for PASG is projected at USD 4.00 over the next 12 months.
This means that PASG's stock price may go up by +1,003.45% over the next 12 months.
We can't find any ETFs which contains Passage Bio Inc's stock.
As per our most recent records Passage Bio Inc has 58 Employees.
Passage Bio Inc's registered address is One Commerce Square, Philadelphia, PA, United States, 19103.
You can get more information about it from Passage Bio Inc's website at https://www.passagebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PASG !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
